Christopher W. Boyce
Research Subjects
Christopher W. Boyce has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Aidan Boving
Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, USA
1 shared publication Allison A. Bauman
Mycobacteria Research Laboratories, Colorado State University, Fort Collins, USA
1 shared publicationAnne J. Lenaerts
Mycobacteria Research Laboratories, Colorado State University, Fort Collins, USA
1 shared publicationAparna Anderson
Gates Medical Research Institute, Cambridge, USA
1 shared publication- Brendan M. Crowley
Discovery Chemistry, Merck & Co., West Point, USA
1 shared publication Charles D. Wells
Gates Medical Research Institute, Cambridge, USA
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 13 January 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (2) , 553-560
Discovery and development of a new oxazolidinone with reduced toxicity for the treatment of tuberculosis
Linezolid, an oxazolidinone, is a cornerstone of treatment regimens for highly drug-resistant tuberculosis but cannot be used in drug-susceptible disease because of toxicity. This toxicity results from inhibition of mammalian mitochondrial protein synthesis. Here we show the development of a new oxazolidinone, MK-7762, with antitubercular activity that is better than linezolid and limited mitochondrial protein synthesis inhibition. The cryogenic electron microscopy structure of the stalled mycobacterial ribosome with MK-7762 revealed the basis for this selectivity. BALB/c mouse models of disease showed MK-7762 reduced lung bacterial burden by a 3-log-fold decrease in an acute model ( N = 18) and a 2-log-fold decrease in chronically infected animals ( N = 18). MK-7762 showed lesion penetration similar to linezolid in C3HeB/FeJ mice. MK-7762 had pharmacokinetic properties predicting low once-daily doses in humans and a favorable 14-day preclinical safety profile in Wistar Han rats ( N = 30) and Beagle dogs ( N = 6). Four-month safety studies in both rats ( N = 20) and dogs ( N = 24) showed no changes in hematology parameters at exposures well above the 100-mg predicted human dose. These data will enable MK-7762 to be explored as a component of new tuberculosis treatment combinations for all forms of the disease.
- 13 January 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (2) , 553-560
Top Cited PapersOpen AccessDiscovery and development of a new oxazolidinone with reduced toxicity for the treatment of tuberculosis
Linezolid, an oxazolidinone, is a cornerstone of treatment regimens for highly drug-resistant tuberculosis but cannot be used in drug-susceptible disease because of toxicity. This toxicity results from inhibition of mammalian mitochondrial protein synthesis. Here we show the development of a new oxazolidinone, MK-7762, with antitubercular activity that is better than linezolid and limited mitochondrial protein synthesis inhibition. The cryogenic electron microscopy structure of the stalled mycobacterial ribosome with MK-7762 revealed the basis for this selectivity. BALB/c mouse models of disease showed MK-7762 reduced lung bacterial burden by a 3-log-fold decrease in an acute model ( N = 18) and a 2-log-fold decrease in chronically infected animals ( N = 18). MK-7762 showed lesion penetration similar to linezolid in C3HeB/FeJ mice. MK-7762 had pharmacokinetic properties predicting low once-daily doses in humans and a favorable 14-day preclinical safety profile in Wistar Han rats ( N = 30) and Beagle dogs ( N = 6). Four-month safety studies in both rats ( N = 20) and dogs ( N = 24) showed no changes in hematology parameters at exposures well above the 100-mg predicted human dose. These data will enable MK-7762 to be explored as a component of new tuberculosis treatment combinations for all forms of the disease.